Prosecution Insights
Last updated: April 19, 2026
Application No. 18/030,336

A METHOD FOR REDUCING ALLERGENS

Non-Final OA §102§112
Filed
Apr 05, 2023
Examiner
ROZOF, TIMOTHY R
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Aqdot Limited
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
2y 2m
To Grant
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allow Rate
690 granted / 951 resolved
+12.6% vs TC avg
Strong +24% interview lift
Without
With
+24.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 2m
Avg Prosecution
32 currently pending
Career history
983
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
20.1%
-19.9% vs TC avg
§102
34.4%
-5.6% vs TC avg
§112
23.5%
-16.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 951 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This is a response to Applicant’s communication filed on December 17, 2025. Application No. 18/030,336, is a 371 of PCT/GB2021/052602, filed October 7, 2021, and claims foreign priority to United Kingdom applications Nos. UNITED KINGDOM 2015926.5, filed October 7, 2020; and UNITED KINGDOM 2016220.2, filed October 13, 2020. Claims 1-15 are pending. Election/Restrictions Applicant's elections with traverse of the invention of Group I and the cucurbituril species of cucurbit[8]uril in the reply filed on December 17, 2025, are acknowledged. The traversal is on the ground(s) that there would be no serious burden on the Office to examine both the full scope of inventions and species claimed. This is not found persuasive because under the PCT rules for Unity of Invention the Office’s burden is not a consideration. Nonetheless, there would be a serious burden on the Office to examine the full scope of the inventions. The generally claimed cucurbiturils, as well as derivatives thereof, are well known in the art and have other uses than those claimed, raising both search as well as enablement issues. The requirement is still deemed proper and is therefore made FINAL. Claim 15 is withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention. Applicants timely traversed the restriction (election) requirements in the reply filed on December 17, 2025. Claims 1-14 are examined below. Claim Rejections - 35 USC § 102(a)(1) The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-14 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Day et al., U.S. 7,501,523. Day discloses a non-therapeutic method for reducing or eliminating the allergic effect of an allergen comprising the step of bringing the allergen into physical contact with an effective amount of a cucurbituril, a derivative thereof, a variant thereof or a mixture thereof. See Day et al., Col. 25, ln. 45 – Col. 26, ln. 37; see Id., specifically, Col. 26, lns. 15-19, for allergens as broadly claimed. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. Claims 1-14 are rejected under 35 U.S.C. 112(a) because the specification, while being enabling for a non-therapeutic method of reducing the effect of an allergen comprising the step of bringing the allergen into physical contact with an effective amount of cucurbit[4]uril–cucurbit[12]uril or mixture thereof, the specification does not reasonably provide enablement for a non-therapeutic method for eliminating the allergic effect of an allergen comprising bringing the allergen into physical contact with cucurbiturils (generally), a derivative thereof, a variant thereof, etc. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims. Factors to be considered when determining whether claims in an application for patent are enabling include (1) the breadth of the claims, (2) the nature of the invention, (3) the state of the prior art, (4) the level of one of ordinary skill, (5) the level of predictability in the art, (6) the amount of direction provided by the inventor, (7) the existence of working examples, and (8) the quantity of experimentation needed to make or use the invention based on the content of the disclosure. See MPEP § 2164.08, citing In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988). The claims are generally drawn to using cucurbiturils generally to reduce or eliminate allergens. However, the specification presents evidence of AqFreshRTM (a known cucurbituril contain product) to a limited effect in reducing some allergens as compared to wiping with water. (See Specification, Figs. 1-3.) The specification provides no other direction as to how cucurbituril, its derivatives or variants can accomplish the same, or eliminate allergens all together. In addition, the prior art fails to provide compensatory guidance. There is therefore no correlation between using AqFreshRTM, eliminating allergens and using any other cucurbiturils variant or derivative to do the same. Accordingly, it would require undue experimentation for the artisan to practice the invention as broadly claimed. Conclusion No claims are allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R ROZOF whose telephone number is (571)270-5992. The examiner can normally be reached on Monday - Friday, 9:00 a.m. -5:00 p.m.. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached on (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Apr 05, 2023
Application Filed
Mar 05, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594259
TREATMENT REGIMEN FOR THE TREATMENT OF NEUROLOGICAL DISEASES OR CONDITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595264
HETEROCYCLIC GLP-1 AGONISTS
2y 5m to grant Granted Apr 07, 2026
Patent 12595255
HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES
2y 5m to grant Granted Apr 07, 2026
Patent 12577204
A SOLUTION OF TEMPO-DERIVATIVES FOR USE AS ELECTROLYTE IN REDOX-FLOW CELLS
2y 5m to grant Granted Mar 17, 2026
Patent 12577205
HYDROGENATION OF IMINES BY PALLADIUM BASED CATALYST
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+24.0%)
2y 2m
Median Time to Grant
Low
PTA Risk
Based on 951 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month